FDA Clears Tempus AI's ECG-MR Tool to Detect Hidden Mitral Regurgitation
TEM has more than doubled off its 52-week low of $40.77.
Summary
Tempus AI received FDA 510(k) clearance for Tempus ECG-MR, an AI product that analyzes standard 12-lead ECGs to flag signs of undiagnosed moderate or severe mitral regurgitation in patients 65 and older with cardiovascular risk factors. This is the company's fourth FDA-cleared ECG-AI product, expanding its cardiology portfolio. The clearance adds a new commercial product to Tempus's precision medicine platform, though revenue impact is not yet quantified. The company recently agreed to acquire Personalis for $1.5B in stock, and this regulatory win supports its broader AI diagnostics strategy.
At the time of this announcement, TEM was trading at $83.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.